Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Rhea-AI Summary

Dogwood Therapeutics (NASDAQ: DWTX), a development-stage biotech company focused on pain and fatigue-related disorders, announced its participation in the upcoming Sidoti Small-Cap Virtual Conference. CEO Greg Duncan will deliver a corporate overview presentation on Wednesday, June 11, 2025, at 9:15 AM ET. The conference runs from June 11-12, 2025, and Duncan will be available for one-on-one meetings with investors. The presentation will be accessible via webcast, and interested parties can register for the conference and schedule meetings through the provided links.

ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025.

Presentation Date:	Wednesday, June 11, 2025
Time:	9:15am Easter Time (Track 1)

Webcast Link: https://sidoti.zoom.us/webinar/register/WN_C6ACWY1kTXGa0eBkFbVd0w

Mr. Duncan will be available for one-on-one meetings. To request a meeting and to register for the conference, click here:

https://www.meetmax.com/sched/event_121351/investor_reg_new.html?attendee_role_id=SIDOTI_INVESTOR

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Na_V 1.7 analgesic program is centered on our lead development candidate, Halneuron^®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). Interim data from the ongoing Halneuron^® Phase 2 CINP study are expected in Q4 of 2025.

Dogwood’s antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.

For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

CORE IR
(516) 222-2560
IR@dwtx.com

FAQ

When is Dogwood Therapeutics (DWTX) presenting at the Sidoti Small-Cap Conference?

Dogwood Therapeutics will present on Wednesday, June 11, 2025, at 9:15 AM Eastern Time during Track 1 of the conference.

Who will represent Dogwood Therapeutics (DWTX) at the Sidoti Conference?

CEO Greg Duncan will represent Dogwood Therapeutics, delivering a corporate overview and being available for one-on-one meetings.

What is Dogwood Therapeutics' (DWTX) main business focus?

Dogwood Therapeutics is a development-stage biotechnology company that develops new medicines for treating pain and fatigue-related disorders.

How can investors attend Dogwood Therapeutics' (DWTX) presentation at the Sidoti Conference?

Investors can attend by registering through the provided webcast link or the conference registration link for the virtual event.